RVPH
Reviva Pharmaceuticals Holdings Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.42M
P/E Ratio
—
EPS
$-3.33
Beta
0.75
52W High
$23.20
52W Low
$0.26
50-Day MA
$0.84
200-Day MA
$6.62
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for central nervous system (CNS) disorders and other critical health issues. The company’s lead candidate, RP5063, presents a unique therapeutic strategy for managing schizophrenia and mood disorders, supported by an innovative drug delivery platform that aims to improve treatment efficacy. Reviva is well-positioned for growth in the dynamic mental health sector, with a robust pipeline and a strong focus on addressing significant unmet medical needs as it navigates key clinical development milestones.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-10.10M |
| Operating Margin | 0.00% |
| Return on Equity | -256.20% |
| Return on Assets | -69.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.47 |
| Price-to-Book | 0.31 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -6.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.11M |
| Float | $11.44M |
| % Insiders | 1.90% |
| % Institutions | 27.72% |
Analyst Ratings
Consensus ($70.00 target)
4
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026